Qiagen (NYSE:QGEN) Downgraded by Wall Street Zen to "Hold"

Key Points

• Qiagen was downgraded from a "buy" rating to a "hold" rating by Wall Street Zen, indicating a cautious outlook on the company's stock performance.
• Analysts have set a range of target prices for Qiagen, with Barclays at $53.00 and UBS Group raising theirs from $48.00 to $50.00, reflecting a mix of positive and neutral sentiment among investment firms.
• The consensus rating for Qiagen's stock is currently a "Hold," with an average target price of $49.40, positioning it as a stable but potentially plateauing investment.

Qiagen (NYSE:QGEN - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday.

A number of other equities analysts also recently commented on the company. Barclays set a $53.00 target price on Qiagen and gave the company an "overweight" rating in a research note on Thursday, October 2nd. UBS Group lifted their target price on Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. Bank of America lifted their target price on Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. Cowen restated a "hold" rating on shares of Qiagen in a research note on Thursday, August 7th. Finally, Weiss Ratings reissued a "hold (c+)" rating on shares of Qiagen in a report on Wednesday. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $49.40.

Qiagen Stock Performance

Shares of QGEN stock opened at $46.93 on Friday. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. The business has a 50 day moving average of $47.11 and a two-hundred day moving average of $45.50. Qiagen has a 52 week low of $37.63 and a 52 week high of $51.88. The company has a market cap of $10.43 billion, a P/E ratio of 27.73, a PEG ratio of 2.46 and a beta of 0.66.

Qiagen (NYSE:QGEN - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting analysts' consensus estimates of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The company had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. During the same period in the previous year, the firm posted $0.55 earnings per share. Qiagen's quarterly revenue was up 7.7% compared to the same quarter last year. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, analysts anticipate that Qiagen will post 2.26 EPS for the current year.

Institutional Trading of Qiagen

Several hedge funds have recently added to or reduced their stakes in QGEN. Wealth Enhancement Advisory Services LLC bought a new stake in Qiagen during the 4th quarter valued at $202,000. GAMMA Investing LLC raised its holdings in Qiagen by 93.9% during the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after purchasing an additional 1,425 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in Qiagen by 2.3% during the first quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock worth $716,000 after purchasing an additional 395 shares in the last quarter. Bank Pictet & Cie Europe AG bought a new stake in Qiagen during the first quarter worth approximately $669,000. Finally, Blue Trust Inc. raised its holdings in Qiagen by 30.5% during the first quarter. Blue Trust Inc. now owns 13,519 shares of the company's stock worth $543,000 after purchasing an additional 3,157 shares in the last quarter. Institutional investors own 70.00% of the company's stock.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.